Clinical efficacy of implementing Bio Immune(G)ene MEDicine in the treatment of chronic asthma with the objective of reducing or removing effectively corticosteroid therapy: A novel approach and promising results

Glady,Gilbert

doi:10.3892/etm.2018.6019

Clinical efficacy of implementing Bio Immune(G)ene MEDicine in the treatment of chronic asthma with the objective of reducing or removing effectively corticosteroid therapy: A novel approach and promising results

Authors:
- Gilbert Glady
View Affiliations

Affiliations: European Bio Immune(G)ene Medecine Association, Internal Medicine, 68000 Colmar, France
Published online on: April 2, 2018 https://doi.org/10.3892/etm.2018.6019
Pages: 5133-5140

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Asthma is one of the diseases that demonstrates a wide range of variation in its clinical expression, in addition to an important heterogeneity in the pathophysiological mechanisms present in each case. The ever‑increasing knowledge of the molecular signalling routes and the development of the Bio Immune(G)ene Medicine [BI(G)MED] therapy in line with this knowledge has revealed a whole novel potential set of self‑regulation biological molecules, that may be used to promote the physiological immunogenic self‑regulation mechanisms and re‑establish the homeostatic balance at a genomic, proteomic and cellular level. The aim of the present study is to demonstrate that the sublingual use of a therapeutic protocol based on BI(G)MED regulatory BIMUREGs in the treatment of chronic asthma may reduce or suppress corticosteroid therapy and avoid its harmful side effects which some patients suffer when using this treatment on a long‑term basis. The clinical efficacy of BI(G)MED for chronic asthma was evaluated through a multi‑centre study carried out in 2016 implementing a 6‑month BI(G)MED treatment protocol for Bronchial Asthma. A total of 61 patients from private medical centres and of European countries including Germany, Austria, France, Belgium and Spain participated. The manuscript describes in detail the clinical efficacy of Bio Immune(G)ene regulatory BI(G)MED treatment protocol that allows the reduction or total removal of the corticosteroid dose in patients with chronic asthma. No adverse reactions were observed. The BI(G)MED regulatory therapy brings novel therapeutic possibilities as an effective and safe treatment of chronic asthma. BI(G)MED was demonstrated to significantly reduce asthma severity when parameter compositions were all analysed by categorical outcomes. Therefore, it is considered a good therapeutic alternative for patients who respond poorly to steroids.

View Figures

View References

1	Mattes J, Collison A, Plank M, Phipps S and Foster PS: Antagonism of microRNA-126 suppresses the effector function of TH2 cells and the development of allergic airways disease. Proc Natl Acad Sci USA. 106:18704–18709. 2009. View Article : Google Scholar : PubMed/NCBI
2	Stott B, Lavender P, Lehmann S, Pennino D, Durham S and Schmidt-Weber CB: Human IL-31 is induced by IL-4 and promotes TH2-driven inflammation. J Allergy Clin Immunol Aug. 132:446–454.e5. 2013. View Article : Google Scholar
3	Nakajima H and Takatsu K: Role of cytokines in allergic airway inflammation. Int Arch Allergy Immunol. 142:265–273. 2007. View Article : Google Scholar : PubMed/NCBI
4	Barrett NA and Austen KF: Innate cells and T helper 2 cell immunity in airway inflammation. Immunity. 31:425–437. 2009. View Article : Google Scholar : PubMed/NCBI
5	Moreira AP, Cavassani KA, Ismailoglu UB, Hullinger R, Dunleavy MP, Knight DA, Kunkel SL, Uematsu S, Akira S and Hogaboam CM: The protective role of TLR6 in a mouse model of asthma is mediated by IL-23 and IL-17A. J Clin Invest. 121:4420–4432. 2011. View Article : Google Scholar : PubMed/NCBI
6	Taft RJ, Pang KC, Mercer TR, Dinger M and Mattick JS: Non-coding RNAs: Regulators of disease. J Pathol. 220:126–139. 2010. View Article : Google Scholar : PubMed/NCBI
7	Foster PS, Plank M, Collison A, Tay HL, Kaiko GE, Li J, Johnston SL, Hansbro PM, Kumar RK, Yang M and Mattes J: The emerging role of microRNAs in regulating immune and inflammatory responses in the lung. Immunol Rev. 253:198–215. 2013. View Article : Google Scholar : PubMed/NCBI
8	Deshpande DA, Dileepan M, Walseth TF, Subramanian S and Kannan MS: MicroRNA regulation of airway inflammation and airway smooth muscle function: Relevance to asthma. Drug Dev Res. 76:286–295. 2015. View Article : Google Scholar : PubMed/NCBI
9	Simpson LJ, Patel S, Bhakta NR, Choy DF, Brightbill HD, Ren X, Wang Y, Pua HH, Baumjohann D, Montoya MM, et al: A microRNA upregulated in asthma airway T cells promotes TH2 cytokine production. Nat Immunol Dec. 15:1162–1170. 2014. View Article : Google Scholar
10	Brook PO, Perry MM, Adcock IM and Durham AL: Epigenome-modifying tools in asthma. Epigenomics. 7:1017–1032. 2015. View Article : Google Scholar : PubMed/NCBI
11	Collison A, Herbert C, Siegle JS, Mattes J, Foster PS and Kumar RK: Altered expression of microRNA in the airway wall in chronic asthma: miR-126 as a potential therapeutic target. BMC Pulm Med. 11:292011. View Article : Google Scholar : PubMed/NCBI
12	Collison A, Mattes J, Plank M and Foster PS: Inhibition of house dust mite-induced allergic airways disease by antagonism of microRNA-145 is comparable to glucocorticoid treatment. J Allergy Clin Immunol. 128:160–167. 2011. View Article : Google Scholar : PubMed/NCBI
13	Li JJ, Tay HL, Maltby S, Xiang Y, Eyers F, Hatchwell L, Zhou H, Toop HD, Morris JC, Nair P, et al: MicroRNA-9 regulates steroid-resistant airway hyperresponsiveness by reducing protein phosphatase 2A activity. J Allergy Clin Immunol. 136:462–473. 2015. View Article : Google Scholar : PubMed/NCBI
14	Calamita Z, Saconato H, Pelá AB and Atallah AN: Efficacy of sublingual immunotherapy in asthma: Systematic review of randomized-clinical trials using the cochrane collaboration method. Allergy. 61:1162–1172. 2006. View Article : Google Scholar : PubMed/NCBI
15	Compalati E, Braido F and Canonica GW: An update on allergen immunotherapy and asthma. Curr Opin Pulm Med. 20:109–117. 2014. View Article : Google Scholar : PubMed/NCBI
16	Moser S, Peroni DG, Comberiati P and Piacentini GL: Asthma and viruses: Is there a relationship? Front Biosci (Elite Ed). 6:46–54. 2014.PubMed/NCBI
17	Metz G and Kraft M: Effects of atypical infections with Mycoplasma and Chlamydia on asthma. Immunol Allergy Clin North Am. 30(575–585): vii–viii. 2010.
18	Kudo M, Ishigatsubo Y and Aoki I: Pathology of asthma. Front Microbiol. 4:2632013. View Article : Google Scholar : PubMed/NCBI
19	Assa'ad AH and Rothenberg ME: Eosinophilic asthma: Insights into the effects of reducing IL-5 receptor-positive cell levels. J Allergy Clin Immunol. 132:1097–1085. 2013. View Article : Google Scholar : PubMed/NCBI
20	Paliwal R, Babu RJ and Palakurthi S: Nanomedicine scale-up technologies: Feasibilities and challenges. AAPS PharmSciTech. 15:1527–1534. 2014. View Article : Google Scholar : PubMed/NCBI
21	Chen LS, Wang AX, Dong B, Pu KF, Yuan LH and Zhu YM: A new prospect in cancer therapy: Targeting cancer stem cells to eradicate cancer. Chin J Cancer. 31:564–572. 2012. View Article : Google Scholar : PubMed/NCBI
22	Winter JM and Tang Y: Synthetic biological approaches to natural product biosynthesis. Curr Opin Biotechnol. 23:736–743. 2012. View Article : Google Scholar : PubMed/NCBI
23	Calabrese EJ: Hormesis is central to toxicology, pharmacology and risk assessment. Hum Exp Toxicol. 29:249–261. 2010. View Article : Google Scholar : PubMed/NCBI
24	Calabrese EJ: The hormesis concept is the most fundamental dose-response in the biomedical and toxicological sciences. Br J Clin Pharmacol. 66:594–617. 2008.PubMed/NCBI
25	Kirchner B, di Dio PJ and Hutter J: Real-world predictions from ab initio molecular dynamics simulations. Top Curr Chem. 307:109–153. 2012. View Article : Google Scholar : PubMed/NCBI
26	Schrauwers A and Poolman B: Synthetische Biologie - Der Mensch als Schöpfer? Springer Spektrum; Heidelberg: 2013, View Article : Google Scholar
27	Melo CA and Melo SA: Biogenesis and Physiology of MicroRNAsNon-Coding RNAs and Cancer. Fabbri M: Springer Science+Business Media, LLC; New York, NY: pp. 5–24. 2013